BlackRock Discloses 5.0% Stake in Amylyx Pharmaceuticals
Ticker: AMLX · Form: SC 13G · Filed: Jan 29, 2024 · CIK: 1658551
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, pharmaceuticals
TL;DR
**BlackRock just revealed a 5.0% stake in Amylyx, signaling institutional confidence.**
AI Summary
BlackRock Inc., a major investment firm, reported on January 29, 2024, that as of December 31, 2023, it holds a significant stake in Amylyx Pharmaceuticals, Inc. This filing indicates BlackRock's ownership of 3,799,008 shares of Amylyx's Common Stock, representing 5.0% of the company. This matters to investors because BlackRock's substantial holding signals confidence in Amylyx, potentially influencing other institutional and retail investors.
Why It Matters
BlackRock's 5.0% ownership in Amylyx Pharmaceuticals, Inc. indicates a major institutional investor's belief in the company, which can be a positive signal for current and prospective shareholders.
Risk Assessment
Risk Level: low — This filing indicates a large institutional investment, generally seen as a positive or neutral development, not increasing risk.
Analyst Insight
A smart investor would view BlackRock's 5.0% stake as a positive signal, potentially indicating institutional confidence in Amylyx Pharmaceuticals, Inc., and might consider further research into the company's fundamentals.
Key Numbers
- 3,799,008 — Shares Owned (Total shares of Amylyx Pharmaceuticals, Inc. Common Stock beneficially owned by BlackRock Inc.)
- 5.0% — Ownership Percentage (Percentage of Amylyx Pharmaceuticals, Inc. Common Stock owned by BlackRock Inc.)
Key Players & Entities
- BlackRock Inc. (company) — the reporting person and major investment firm
- Amylyx Pharmaceuticals, Inc. (company) — the subject company in which BlackRock holds shares
- 3,799,008 (dollar_amount) — number of shares of Common Stock beneficially owned by BlackRock
- 5.0% (dollar_amount) — percentage of Amylyx Pharmaceuticals, Inc. Common Stock owned by BlackRock
- December 31, 2023 (person) — the date of the event which required the filing of this statement
- January 29, 2024 (person) — the filing date of the SC 13G
Forward-Looking Statements
- Other institutional investors may increase their positions in Amylyx Pharmaceuticals, Inc. following BlackRock's disclosure. (Amylyx Pharmaceuticals, Inc.) — medium confidence, target: Q2 2024
FAQ
What type of filing is this and who filed it?
This is an SC 13G filing, which was filed by BlackRock Inc. regarding its ownership in Amylyx Pharmaceuticals, Inc.
What is the specific date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 31, 2023.
How many shares of Amylyx Pharmaceuticals, Inc. Common Stock does BlackRock Inc. beneficially own?
BlackRock Inc. beneficially owns 3,799,008 shares of Amylyx Pharmaceuticals, Inc. Common Stock.
What percentage of Amylyx Pharmaceuticals, Inc. does BlackRock Inc.'s ownership represent?
BlackRock Inc.'s ownership represents 5.0% of the Common Stock of Amylyx Pharmaceuticals, Inc.
Under which rule was this Schedule 13G filed?
This Schedule 13G was filed under Rule 13d-1(b).
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 29, 2024 by December 31, 2023 regarding Amylyx Pharmaceuticals, Inc. (AMLX).